EDITOR’S CHOICE ARTICLE – Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors

Journal Name: Clinical Cancer Drugs

Author(s): Atasi De Chatterjee, Debarshi Roy, Priscilla Guevara, Rituraj Pal, Mahesh Narayan, Sukla Roychowdhury, Siddhartha Das*.




Graphical Abstract:




Background: The migration of tumor cells is critical in spreading cancers through the lymphatic nodes and circulatory systems. Although arachidonic acid (AA) and its soluble metabolites have been shown to induce the migration of breast and colon cancer cells, the mechanism by which it induces such migration has not been fully understood.

Objective: The effect of AA on migratory responses of the MDA-MB-231 cell line (a triple-negative breast cancer cell) was examined and compared with MCF-7 (estrogen-receptor positive) breast cancer cells to elucidate the mechanism of AA-induced migration.

Methods: Migrations of breast cancer cells were examined with the help of wound-healing assays. AA-induced eicosanoid synthesis was monitored by RP-HPLC. Cellular localizations of lipoxygenase and lipid rafts were assessed by immunoblot and confocal microscopy.

Results: AA treatment stimulated the synthesis of leukotriene B4 (LTB4) and HETE-8, but lowered the levels of prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), and HETE-5 in MDA-MB-231 cells. Further analysis indicated that AA increased the expression of 5-lipoxygenase (5-LOX) in this cell line and inhibiting its expression by small molecule inhibitors lowered the production of LTB4 and reduced migration. In contrast, MCF-7 cells did not show any appreciable changes in eicosanoid synthesis, 5-LOX expression, or cellular migration.

Conclusion: Our results suggest that AA treatment activates the BLT1 receptor (present in membrane microdomains) and stimulates the synthesis of LTB4 production, which is likely to be associated with the migration of MDA-MB-231 cells.



For more details, please visit: http://www.eurekaselect.com/161381/article



Dr-Giulio Francia



Editor-in-Chief: Clinical Cancer Drugs

The University of Texas
El Paso, TX


Clinical Cancer Drugs publishes original research and (as well as) expert reviews, and thematic issues in all core areas of translational and clinical cancer drug research.

The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading to clinical oncologists, toxicologists, medicinal chemists, and to pharmacologists.


Articles from the journal Clinical Cancer Drugs, Volume 4, Issue 2:

For details on the articles, please visit this link : http://bit.ly/2Divk6w


World Tuberculosis Day 2017!


World Tuberculosis Day, observed on March 24 each year, is designed to build public awareness about the global epidemic of tuberculosis (TB) and efforts to eliminate the disease. World TB Day is one of eight official global public health campaigns marked by the World Health Organization (WHO).

Bentham Science journals publish papers that present top quality research on this particular disease. Find the latest studies in the following journals:

Infectious Disorders – Drug Targets

Clinical Cancer Drugs

Open Access Article: Novel Antibody Therapeutics Targeting Mesothelin in Solid Tumors

Journal: Clinical Cancer Drugs

Author(s): Xiao-Yan Zhao, Babu Subramanyam, Nenad Sarapa, Sven Golfier and Harald Dinter

Affiliation: Ph.D. 455 Mission Bay Blvd. (South), San Francisco, USA


Abstract: Monoclonal antibodies have become attractive clinical anti-cancer drugs in the last 3 decades due to their targeting specificity and suitable pharmacokinetic properties. Their treatment modalities include unconjugated antibodies, radioimmunotherapy, immunotoxins and antibody-drug conjugates. Mesothelin is a tumor-associated antigen, a glycosyl-phosphatidylinositol (GPI)-anchored glycoprotein, which is frequently over-expressed on the cell membrane of a number of epithelial malignancies and shows limited expression in non-malignant tissues. Mesothelin has been validated as a suitable target for cancer therapy. A number of unconjugated antibodies, immunotoxins and antibody-drug conjugates targeting mesothelin have been developed in recent years to treat solid tumors, some of them yielding promising results in early clinical evaluation. This review will focus on the recent development of novel antibody therapeutics targeting mesothelin in diseases of mesothelioma, pancreatic, ovarian, lung, triple negative breast and gastric cancers. Their mechanisms of action and preclinical/clinical data will also be discussed.

To read the complete research article, visit: http://benthamscience.com/journals/clinical-cancer-drugs/article/139615/

New Issues of various Bentham Science Journals

Current Drug Targets, 17 Issue 6


Current Physical Chemistry, 6 Issue 1


Current Drug Metabolism, 17 Issue 5


Current Alzheimer Research, 13 Issue 5


Current Molecular Imaging, 4 Issue 2


Current Medicinal Chemistry, 23 Issue 9


Current Cancer Therapy Reviews, 11 Issue 4


Current Chemical Biology, 9 Issue 2


Clinical Cancer Drugs, 3 Issue 1


Recent Issues

World Tuberculosis Day 2016!


World Tuberculosis Day is observed every year on the 24th of March, with the intentions of eradicating this epidemic disease. The journals of Bentham Science related to this day are;

Clinical Cancer Drugs

Infectious Disorders – Drug Targets



Chemical Abstracts Service (CAS) indexes Current Chromatography and Clinical Cancer Drugs:

Chemical Abstracts Service, a division of the American Chemical Society accepts to index two new journals Current Chromatography and Clinical Cancer Drugs published by Bentham Science Publishers.

Chemical Abstracts Service (CAS) aims to deliver comprehensive and useful digital information environment for scientific research and discovery. 

Current Chromatography is an international peer-reviewed journal, which publishes expert reviews, original research articles and thematic issues in all core areas of separation science. For details, please visit the journal website at:http://benthamscience.com/journal/index.php?journalID=cchg.

Clinical Cancer Drugs publishes original research, expert reviews, and thematic issues in all core areas of translational and clinical cancer drug research. For details, please visit the journal website at: http://benthamscience.com/journal/index.php?journalID=ccand.

For more details, visit: http://benthamscience.com/press-release-main.php

%d bloggers like this: